96 related articles for article (PubMed ID: 16686369)
41.
Patel M; Kumar A; Jayawardena D; Priyamvada S; Anbazhagan AN; Alrefai WA; Gill RK; Dudeja PK; Saksena S
Gene Rep; 2020 Mar; 18():. PubMed ID: 32864506
[TBL] [Abstract][Full Text] [Related]
42. Intestinal drug transporters in pathological states: an overview.
Drozdzik M; Czekawy I; Oswald S; Drozdzik A
Pharmacol Rep; 2020 Oct; 72(5):1173-1194. PubMed ID: 32715435
[TBL] [Abstract][Full Text] [Related]
43. Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats.
Song YK; Yoon JH; Woo JK; Kang JH; Lee KR; Oh SH; Chung SJ; Maeng HJ
Pharmaceutics; 2020 Apr; 12(5):. PubMed ID: 32357395
[TBL] [Abstract][Full Text] [Related]
44. Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells.
Wang JQ; Li JY; Teng QX; Lei ZN; Ji N; Cui Q; Zeng L; Pan Y; Yang DH; Chen ZS
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085398
[TBL] [Abstract][Full Text] [Related]
45. Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in mice.
Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
Pharmacol Res Perspect; 2020 Feb; 8(1):e00544. PubMed ID: 31988753
[TBL] [Abstract][Full Text] [Related]
46. Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.
Robinson AN; Tebase BG; Francone SC; Huff LM; Kozlowski H; Cossari D; Lee JM; Esposito D; Robey RW; Gottesman MM
Drug Metab Dispos; 2019 Jul; 47(7):715-723. PubMed ID: 31048454
[TBL] [Abstract][Full Text] [Related]
47. Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.
Miyata H; Takada T; Toyoda Y; Matsuo H; Ichida K; Suzuki H
Front Pharmacol; 2016; 7():518. PubMed ID: 28082903
[TBL] [Abstract][Full Text] [Related]
48. Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines.
Gotanda K; Hirota T; Saito J; Fukae M; Egashira Y; Izumi N; Deguchi M; Kimura M; Matsuki S; Irie S; Ieiri I
Sci Rep; 2016 Aug; 6():32299. PubMed ID: 27571936
[TBL] [Abstract][Full Text] [Related]
49. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
50. Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids.
Klaassen CD; Cui JY
Drug Metab Dispos; 2015 Oct; 43(10):1505-21. PubMed ID: 26261286
[TBL] [Abstract][Full Text] [Related]
51. Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene.
Gotanda K; Tokumoto T; Hirota T; Fukae M; Ieiri I
Br J Clin Pharmacol; 2015 Nov; 80(5):1236-7. PubMed ID: 25872459
[No Abstract] [Full Text] [Related]
52. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
Karibe T; Hagihara-Nakagomi R; Abe K; Imaoka T; Mikkaichi T; Yasuda S; Hirouchi M; Watanabe N; Okudaira N; Izumi T
Pharm Res; 2015 May; 32(5):1634-47. PubMed ID: 25380981
[TBL] [Abstract][Full Text] [Related]
53. A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2).
Wu B; Jiang W; Yin T; Gao S; Hu M
Pharm Res; 2012 Nov; 29(11):3199-208. PubMed ID: 22752253
[TBL] [Abstract][Full Text] [Related]
54. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Karlgren M; Vildhede A; Norinder U; Wisniewski JR; Kimoto E; Lai Y; Haglund U; Artursson P
J Med Chem; 2012 May; 55(10):4740-63. PubMed ID: 22541068
[TBL] [Abstract][Full Text] [Related]
55. The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP.
Barrera B; Otero JA; Egido E; Prieto JG; Seelig A; Álvarez AI; Merino G
Antimicrob Agents Chemother; 2012 Jul; 56(7):3535-43. PubMed ID: 22508302
[TBL] [Abstract][Full Text] [Related]
56. Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway.
Hamdan AM; Koyanagi S; Wada E; Kusunose N; Murakami Y; Matsunaga N; Ohdo S
J Biol Chem; 2012 May; 287(21):17224-17231. PubMed ID: 22396548
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.
Kusuhara H; Furuie H; Inano A; Sunagawa A; Yamada S; Wu C; Fukizawa S; Morimoto N; Ieiri I; Morishita M; Sumita K; Mayahara H; Fujita T; Maeda K; Sugiyama Y
Br J Pharmacol; 2012 Jul; 166(6):1793-803. PubMed ID: 22300367
[TBL] [Abstract][Full Text] [Related]
58. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T; Ross DD
Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
[TBL] [Abstract][Full Text] [Related]
59. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data.
Abdel-Tawab M; Werz O; Schubert-Zsilavecz M
Clin Pharmacokinet; 2011 Jun; 50(6):349-69. PubMed ID: 21553931
[TBL] [Abstract][Full Text] [Related]
60. Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice.
Saksena S; Goyal S; Raheja G; Singh V; Akhtar M; Nazir TM; Alrefai WA; Gill RK; Dudeja PK
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1115-23. PubMed ID: 21350189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
